Stockscreener 앱 받기
16.75
0.36%
0.06
Bicara Therapeutics Inc 주식(BCAX)의 최신 뉴스
BCAX: De-Risked FORTIFI-HN01 Path, Differentiated Ficera Profile, and Solid Cash Runway Underpin Buy Rating and $28 Target - TipRanks
Bicara Therapeutics stock maintains Buy rating at BTIG on clinical progress - Investing.com Nigeria
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bicara Therapeutics Inc. (BCAX), NewAmsterdam Pharma Company (NAMS) and GE Healthcare Technologies Inc (GEHC) - The Globe and Mail
Does Bicara Therapeutics Inc align with a passive investing strategyDividend Hike & Weekly Market Pulse Updates - baoquankhu1.vn
H.C. Wainwright reiterates Buy rating on Bicara Therapeutics stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on Bicara Therapeutics stock - Investing.com
How cyclical is Bicara Therapeutics Inc.’s revenue stream2025 Market Outlook & Daily Growth Stock Investment Tips - bollywoodhelpline.com
Bicara Therapeutics (NASDAQ:BCAX) Given Outperform Rating at Wedbush - Defense World
Growth Report: Will Bicara Therapeutics Inc. stock continue upward momentumJuly 2025 Opening Moves & Weekly Breakout Watchlists - Bộ Nội Vụ
Wedbush Reaffirms Outperform Rating for Bicara Therapeutics (NASDAQ:BCAX) - MarketBeat
Bicara selects optimal dose for head and neck cancer drug in pivotal study - Investing.com Nigeria
Bicara Therapeutics Touts Breakthrough Ficerafusp Data, Picks 1,500 mg Dose for FORTIFY-HNS Trial - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Shares Down 7%Time to Sell? - MarketBeat
Bicara Sets Phase 3 Path for Ficerafusp Alfa - TipRanks
Bicara Therapeutics announces phase 3 optimal dose and provides 2026 corporate outlook - marketscreener.com
Bicara Therapeutics Inc Announces Phase 3 Optimal Dose and 2026 Outlook - TradingView — Track All Markets
Bicara Therapeutics Announces Phase 3 Optimal Dose And Provides 2026 Corporate Outlook - TradingView — Track All Markets
Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook - GlobeNewswire
Published on: 2026-01-12 06:24:33 - moha.gov.vn
Bicara Therapeutics (NASDAQ:BCAX) Trading 7.8% Higher – Should You Buy? - Defense World
Is Bicara Therapeutics Inc. stock trading at a premium valuationWeekly Trade Review & Precise Trade Entry Recommendations - ulpravda.ru
BTIG Research Begins Coverage on Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Bicara Therapeutics Inc.Common Stock (NQ: BCAX - FinancialContent
Bicara Therapeutics (NASDAQ:BCAX) Trading Up 7.8%Here's Why - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Upgraded to "Strong-Buy" at BTIG Research - MarketBeat
Published on: 2026-01-09 02:43:58 - Улправда
Is Bicara Therapeutics Inc. stock a defensive play in 2025July 2025 Breakouts & Safe Entry Trade Signal Reports - Улправда
Bicara Therapeutics Inc. (BCAX) Stock Analysis: Unveiling an 83.84% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Upcoming EventsBicara Therapeutics Inc.Common Stock (Nasdaq:BCAX) Detailed Stock Data - FinancialContent
BTIG Initiates Coverage of Bicara Therapeutics (BCAX) with Buy Recommendation - Nasdaq
Los Angeles Daily NewsBicara Therapeutics Inc.Common Stock (Nasdaq:BCAX) Price Chart - FinancialContent
History Review: Can Bicara Therapeutics Inc. stock deliver sustainable ROEMarket Risk Summary & Real-Time Market Sentiment Reports - ulpravda.ru
What hedge fund activity signals for Bicara Therapeutics Inc. stockQuarterly Profit Summary & AI Based Trade Execution Alerts - Улправда
Bicara Therapeutics initiated with a Buy at BTIG - TipRanks
BTIG initiates coverage on Bicara Therapeutics stock with Buy rating By Investing.com - Investing.com South Africa
BTIG Research Initiates Coverage on Bicara Therapeutics With Buy Rating, $28 Price Target - MarketScreener
BTIG initiates coverage on Bicara Therapeutics stock with Buy rating - Investing.com
News | postregister.comBicara Therapeutics Inc.Common Stock (Nasdaq:BCAX) Stock Quote - FinancialContent
Can Bicara Therapeutics Inc. stock rebound after recent weaknessEarnings Date Calendar & Free Grow Wealth With Picks - Улправда
Bicara Therapeutics: How InvestingPro’s overvaluation call led to 39% decline By Investing.com - Investing.com South Africa
Bicara Therapeutics management to meet with Cantor Fitzgerald - MSN
Will Bicara Therapeutics Inc. stock continue dividend increases2026 world cup usa national team group stage playmakers pressing system winner prediction preview - Улправда
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of “Hold” from Analysts - Defense World
What Drawdown Risk Means for Long Term Holders of Clean Science and Technology LimitedStock Buyback Announcements & Zero-Cost Stock Research by Professionals - earlytimes.in
Wedbush Initiates Coverage of Bicara Therapeutics (BCAX) with Outperform Recommendation - MSN
Bicara Therapeutics (NASDAQ:BCAX) Trading 3.9% Higher – Here’s Why - Defense World
Aug Chart Watch: What hedge fund activity signals for Bicara Therapeutics Inc stockWeekly Market Outlook & Daily Profit Maximizing Tips - moha.gov.vn
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Up 3.9%Still a Buy? - MarketBeat
Straddle Buy Call Buy Put at same strikeEarnings Call Summaries & Exceptional Return Growth - bollywoodhelpline.com
Hyep Ivan, Bicara Therapeutics CFO, sells $168k in BCAX stock - Investing.com India
Hyep Ivan, Bicara Therapeutics CFO, sells $168k in BCAX stock By Investing.com - Investing.com Nigeria
Bicara Therapeutics (BCAX) Valuation After Dual Biotechnology Index Additions - Yahoo Finance
4.73%
0.92%
자본화:
|
볼륨(24시간):